Aperbio pioneers in-depth hematologic research through strategic academic collaborations. By addressing critical challenges and unmet clinical needs, we have developed a comprehensive portfolio of digital PCR (dPCR) reagent kits and assays. Our solutions empower precision detection of minimal residual disease (MRD), fusion genes, and gene mutations, etc., advancing both research and diagnostic applications in leukemia, lymphoma, and myeloma.